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AbsTrACT
Objective The aim of our study was to determine if a 
genetic background of high blood pressure is a survival 
factor in preterm infants.
Design Prospective cohort study.
setting Patients were enrolled in 53 neonatal intensive 
care units.
Patients Preterm infants with a birth weight below 
1500 g.
Exposures Genetic score blood pressure estimates 
were calculated based on adult data. We compared 
infants with high genetic blood pressure estimates 
(>75th percentile of the genetic score) to infants with 
low genetic blood pressure estimates (<25th percentile 
of the genetic score).
Main outcome measures Lowest blood pressure on 
the first day of life and mortality.
results 5580 preterm infants with a mean gestational 
age of 28.1±2.2 weeks and a mean birth weight of 
1022±299 g were genotyped and analysed. Infants with 
low genetic blood pressure estimates had significantly 
lower blood pressure if compared with infants with 
high genetic blood pressure estimates (27.3±6.2vs 
27.9±6.4, p=0.009, t- test). Other risk factors for low 
blood pressure included low gestational age (−1.26 mm 
Hg/week) and mechanical ventilation (−2.24 mm Hg, 
p<0.001 for both variables, linear regression analysis). 
Mortality was significantly reduced in infants with high 
genetic blood pressure estimates (28- day mortality: 
21/1395, 1.5% vs 44/1395, 3.2%, p=0.005, Fisher’s 
exact test). This survival advantage was independent of 
treatment with catecholamines.
Conclusions Our study provides first evidence that 
a genetic background of high blood pressure may be 
beneficial with regard to survival of preterm infants.
InTrODuCTIOn
In all neonates blood pressure gradually increases 
during the first weeks of life. In preterm infants, 
blood pressure at birth is closely related to gesta-
tional age.1 Considerable uncertainty exists with 
regard to the relevance and treatment of low 
blood pressure.2 In observational studies, low 
blood pressure is associated with death and other 
adverse outcomes like intraventricular haemor-
rhage, periventricular leukomalacia and broncho-
pulmonary dysplasia.3–6 However, most adverse 
short- term and long- term outcomes are reported in 
infants with low blood pressure who were treated 
with catecholamines.3 6–8 These data raise the 
question whether arterial hypotension itself or the 
treatment of the condition with catecholamines is 
harmful. Many neonatologists therefore consider 
low arterial blood pressure not as an indication for 
urgent medical intervention, if a baby is otherwise 
stable.8–10 However, experience in adults, chil-
dren, and several observational studies in preterm 
infants3–6 11 12 promote a different approach with 
early volume replacement and intravenous appli-
cation of catecholamines to prevent prolonged 
hypotension. As of yet, no large- scale randomised 
controlled trials of catecholamine treatment in 
preterm infants have been published.13 14 
In adults, blood pressure is in part a heritable 
trait and the predisposition for high or low blood 
pressure is randomly inherited at the time of 
fertilisation. Therefore, genetically determined 
blood pressure scores are independent from main 
confounders of outcome in preterm infants. We 
genotyped a large number of preterm infants for 
validated genetic polymorphisms influencing blood 
pressure in adults.15 The aim of our study was to 
What is already known on this topic?
 ► No large- scale randomised trials concerning 
the treatment of low blood pressure in preterm 
infants have been published so far.
 ► Observational data in preterm infants are 
conflicting since low blood pressure is 
associated with a number of risk factors for 
adverse outcomes.
What this study adds?
 ► A genetic background of high blood pressure 
was associated with reduced mortality in 
preterm infants which was not altered by 
catecholamine therapy.
 ► Our data give the first evidence that genetic 
predisposition for high blood pressure is 
evolutionary beneficial and that current 
concepts of therapy are not sufficient.
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determine if a genetic background of high blood pressure is a 
survival factor in preterm infants.
METhODs
study design and participants
The German Neonatal Network (GNN) collected data in a 
prospective cohort study. Preterm infants with a birth weight 
below 1500 g who were admitted to one of the participating 
study centres were eligible. After informed parental consent, a 
predefined clinical data set was recorded for each patient. Data 
quality was ensured by regular onsite monitoring of participating 
centres. All data were entered in a database by health record 
administrators at the main GNN office at the University of 
Lübeck, Germany.
Infants were selected for genetic analysis if chip genotyping 
data were available and if their maternal descent was European. 
In multiples, only one infant per twin pair or triplet was selected 
for the genetic analysis by using the random generator of the ‘R’ 
statistical computing software. We furthermore excluded infants 
without recorded lowest blood pressure data on the first day of 
life and infants with a gestational age above 31+6 weeks at birth. 
All selected infants were enrolled in the GNN between 2009 and 
2016. Details of patient selection are given in online supplemen-
tary figure 1.
Exposures
Published risk factors for low blood pressure in preterm infants 
include low gestational age, lack of antenatal administration 
of steroids, mechanical ventilation, multiple birth, emergency 
caesarean section and 5 min APGAR score below 7.4 16 We anal-
ysed the effect of these factors on the lowest mean blood pres-
sure levels on day 1 in a linear regression analysis and included 
the individual gsBP of each infant as a continuous covariate.
Delayed cord clamping and cord milking is also associated 
with higher blood pressure16 and reduces mortality in preterm 
infants,17 but was not recorded in the GNN on an individual 
basis. Therefore, the effect of late cord clamping and cord 
milking could not be assessed in our study. However, due to site- 
specific questionnaires we know that about 90% of all newborn 
intensive care units participating in the GNN do either late cord 
clamping or cord milking or both.
Birth weight, sex and small for gestational age status (defined 
as birth weight <10th percentile)18 are reported as descriptive 
data.
Genotyping
Umbilical cord tissue of participating infants was collected after 
birth and stored at −20°C until transfer to the University of 
Lübeck. DNA was extracted by standard procedures (Gentra 
Puregene Tissue Kit, Qiagen, Hilden, Germany). Chip geno-
typing was done by the Cologne Center for Genomics using 
‘Axiom CEU’ (Affymetrix, Santa Clara, California, USA) or 
the Institute of Clinical Molecular Biology Kiel using ‘Global 
Screening Array (GSA)’ (Illumina, San Diego, California, USA). 
After chip genotyping of approximately 500 000 single nucle-
otide polymorphisms (SNPs) per infant, additional SNPs were 
imputed. After imputation and quality control, validated SNPs 
associated with blood pressure in European adults (n=267) 
were selected.15 Fourteen SNPs were not available in the 
Axiom- CEU datasets and 16 in the GSA datasets. Two hundred 
thirty- seven SNPs were available in both datasets and used for this 
analysis. Many SNPs associated with blood pressure in adults are 
located close to genes which are expressed in venous or arterial 
vessels. Expression in cardiopulmonary tissue was less frequently 
observed.15 Details of selected and excluded SNPs are given 
in online supplementary table 1. Genetic score blood pressure 
(gsBP) was calculated based on adult beta estimates according 
to reference 15 by: gsBP=(gsBP diastolic+gsBP systolic)/2. An 
example how gsBP scores in preterm infants were calculated is 
given in online supplementary table 1.
If groups of adults are compared, differences in cumulated 
beta estimates are closely linked to differences in mean blood 
pressure (in mm Hg).15 Since mean blood pressure in preterm 
infants is much lower than in adults, we expected that adult beta 
estimates will not reflect differences in preterm infants (in mm 
Hg). Therefore, we compared infants with low genetic beta esti-
mates (gsBP <P25) with infants with high genetic beta estimates 
(gsBP >P75). Data of infants with intermediate beta estimates 
(P25–P75) are given as descriptive data only.
Outcomes
The only blood pressure recorded in the GNN dataset is the 
lowest mean blood pressure on the first day of life.4 We 
compared measured lowest mean blood pressure on the first day 
of life between infants with low and high genetic beta estimates 
for blood pressure.
According to our previous publication,4 we selected all- cause 
mortality during the stay in the hospital as the primary end point 
of our analysis. We also analysed neonatal mortality (within the 
first 28 days of life). Common complications of premature birth 
were analysed as secondary end points. Intraventricular haem-
orrhage (IVH) was defined as localised bleeding in the germinal 
matrix (grade I), blood filling up to 50% of a ventricle (grade 
II), blood filling >50% of a ventricle (grade III) and IVH of any 
stage with additional periventricular haemorrhagic infarction 
(grade IV) according to Papile et al.19 Periventricular leukoma-
lacia (PVL) was defined as parenchymal cystic lesions in the 
periventricular region. Bronchopulmonary dysplasia (BPD) was 
defined as need of oxygen or respiratory support (continuous 
positive airway pressure or mechanical ventilation) at 36+0 
weeks postmenstrual gestational age. Sepsis was defined as blood 
culture- proven sepsis with at least two clinical signs. Necrotising 
enterocolitis was defined as necrotising intestinal inflamma-
tion requiring surgery. Retinopathy of prematurity (ROP) was 
defined as ROP requiring treatment. Persistent ductus arteriosus 
(PDA) was defined as surgical closure of PDA. Missing data were 
not imputed.
statistics
Data were analysed with SPSS statistics V.25.0 (IBM, New York, 
USA). The type I error level was set to 0.05. All p values given 
are two- sided. To test for group differences, we compared infants 
with low genetic blood pressure estimates (<P25) and infants 
with high genetic blood pressure estimates by Fisher's exact 
test and t- test. To estimate the direct effect of the adult genetic 
risk score beta estimates on preterm infant blood pressure, we 
entered crude genetic risk scores beta estimates of preterm 
infants in a linear regression model including gestational age, 
lack of antenatal administration of steroids, mechanical venti-
lation, multiple birth, emergency caesarean section and 5 min 
APGAR score below 7.
rEsulTs
A total number of 5580 infants were available for gsBP analysis 
(see online supplementary figure 1). Preterm infant effect allele 
frequencies for individual SNPs are given in online supplementary 
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Gestational age (weeks) 28.0±2.2 28.2±2.2 28.2±2.2 0.02
Birth weight (g) 1021±291 1023±303 1023±299 0.86
Girls (%) 46.7 47.8 47.2 0.85
Multiple birth (%) 28.7 27.1 28.9 0.93
Small for gestational age (%) 11.1 12.8 12.7 0.22
Lowest mean blood pressure on the first day of life (mm Hg) 27.3±6.2 27.6±6.4 27.9±6.4 0.009
*Two- sided p value comparing groups with low vs high gsBP. Gestational age, birth weight and mean blood pressure are given as mean±SD and compared with t- test. Fisher’s 
exact test was used to compare all other variables.
Table 2 Effect size of clinical and genetic factors influencing measured lowest mean blood pressure in preterm infants on the first day of life
Exposure
number of infants 
exposed
lowest mean blood pressure on 
day 1 in exposed infants (mm hg) 
mean±sD
Effect size in linear 
regression analysis
(mm hg) (95% CI) P value*
All infants 5380 27.7±6.3 n.a.
Higher gestational age (per week) 5380 n.a. +1.18 (+1.10 to +1.25) <0.001
Antenatal treatment with steroids 4939 27.8±6.3 +1.01 (+0.47 to +1.56) <0.001
Genetic score blood pressure (per cumulated beta- coefficient) 5380 n.a. +0.06 (+0.01 to +0.12) 0.032
APGAR score <7 at 5 min 959 25.3±6.2 −0.01 (−0.41 to +0.40) 0.967
Multiple birth 1504 27.6±6.5 −0.64 (−0.96 to −0.31) <0.001
Birth by emergency caesarean section 571 26.0±5.9 −0.87 (−1.35 to −0.39) <0.001
Mechanical ventilation on the first day of life 2253 25.0±5.8 −2.24 (−2.58 to −1.91) <0.001
*Linear regression analysis was limited to 5380 infants due to missing data for APGAR score (n=178) and emergency caesarean section (n=24).
n.a., not available.
table 1 and were very similar to adults. Cumulated beta coef-
ficients and thresholds for gsBP quartiles are given in online 
supplementary figure 2. Clinical data for infants with different 
gsBP are given in table 1. Mean gestational age was about 1 day 
higher in infants with high gsBP if compared with infants with 
low gsBP. Infants with high gsBP had significantly higher mean 
blood pressure on the first day of life. However, the total effect 
of the genetic score on minimal blood pressure during the first 
24 hours in preterm infants was <1 mm Hg.
To estimate the effects of clinical factors influencing blood 
pressure on the first day of life, we conducted a linear regres-
sion analysis (table 2). Gestational age and mechanical ventila-
tion were the strongest predictors of blood pressure on the first 
day of life. Antenatal treatment with steroids increased blood 
pressure. Multiple birth and emergency caesarean section were 
associated with reduced blood pressure. Blood pressure on the 
first day of life in preterm infants with different clinical risk 
profiles is given in online supplementary table S2. Infants who 
were mechanically ventilated with one or more additional risk 
factors had lowest mean blood pressure values on the first day 
of life which were 24.3±5.7 mm Hg, although mean gestational 
age in this group was 27.1±2.2 weeks. More than 40% of these 
infants were treated with catecholamines during their stay in the 
hospital.
Adult gsBP was significantly associated with blood pressure 
in preterm infants on the first day of life, but the effect size was 
small. One mm Hg increase in adult gsBP was associated with a 
0.06 mm Hg increased blood pressure in preterm infants on the 
first day of life (table 2). Treatment with catecholamines strati-
fied to gsBP is given in online supplementary table S3. Infants 
with high gsBP received less epinephrine. No other differences 
were observed.
A significantly lower mortality rate was observed in infants 
with high gsBP. Forty of 1395 (2.9%) infants with high gsBP 
died compared with 63 of 1395 (4.5%) infants with low gsBP 
(p=0.027, OR 0.62, 95% CI 0.42 to 0.93, Fisher’s exact test). 
This was in particular due to a reduced mortality within the first 
28 days of life (high gsBP: 1.5% vs low gsBP 3.2%, p=0.005, 
OR 0.47, 95% CI 0.28 to 0.79, Fisher’s exact test). Mortality 
stratified for catecholamine treatment and gsBP is given in 
figure 1. Infants receiving catecholamines (n=1096) if compared 
with infants who were not treated with catecholamines had a 
20- fold increased mortality within 28 days (9.9% vs 0.5%), and 
during the stay in the hospital (15.8% vs 0.8%). However, if 
stratified for gsBP, infants with a predisposition for high gsBP 
had significantly lower 28 days mortality rates even if treated 
with catecholamines (figure 1). In a logistic regression analysis 
with 28- day mortality as dependent variable, lower measured 
blood pressure on the first day of life and a genetic background 
of low blood pressure and treatment with catecholamines were 
associated with higher mortality rates (table 3).
Descriptive data for complications of premature birth are 
given in table 4. Infants with high gsBP had lower rates of IVH 
and lower rates of surgery for PDA.
DIsCussIOn
The main finding of our study is a survival advantage of preterm 
infants with a genetic background of elevated adult blood pres-
sure. Many of the clinical factors which were associated with 
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Figure 1 Mortality within the first 28 days of life stratified for genetic score blood pressure (gsBP) and treatment with catecholamines Treated 
infants: 28- day mortality, high vs low gsBP: p=0.015 (OR 0.48, 95% CI 0.26 to 0.87), Fisher’s exact test.
Table 3 Logistic regression of 28- day mortality
Exposure number of infants exposed
Mortality in exposed 
infants (%)
Or (95% CI) for 28- day 
mortality in multivariate 
logistic regression analysis P value*
All infants 5380 2.4 n.a. n.a.
Higher gestational age (per week) 5380 n.a. 0.81 (0.73 to 0.90) <0.001
Antenatal treatment with steroids 4939 2.2 0.66 (0.38 to 1.17) 0.15
Measured lowest mean blood pressure on day 1 (per 
additional mm Hg)
5380 n.a. 0.96 (0.92 to 0.998) 0.038
Genetic score blood pressure >P75 1340 1.6 Ref. Ref.
Genetic score blood pressure P25–P75 2689 2.4 1.55 (0.90 to 2.68) 0.11
Genetic score blood pressure <P25 1351 3.2 2.10 (1.18 to 3.74) 0.012
APGAR score <7 at 5 min 959 5.3 1.36 (0.89 to 2.06) 0.15
Multiple birth 1504 2.9 1.55 (1.02 to 2.35) 0.039
Birth by emergency caesarean section 571 4.0 1.34 (0.79 to 2.29) 0.28
Mechanical ventilation on the first day of life 2253 4.6 1.64 (0.97 to 2.76) 0.065
Dopamine 512 8.4 0.98 (0.62 to 1.54) 0.92
Dobutamine 595 9.9 1.83 (1.18 to 2.83) 0.007
Norepinephrine 299 12.7 1.76 (1.08 to 2.88) 0.023
Epinephrine 297 23.2 9.90 (6.47 to 15.1) <0.001
n.a., not available.
blood pressure on the first day of life in our study have been 
reported previously.4 16 Due to the large size of our study, we 
were able to quantify the combined effects of these factors. 
These data should be helpful for clinicians who are uncertain if 
a preterm baby will need (eg, arterial umbilical) lines to monitor 
and treat low blood pressure.
In our cohort, infants with catecholamine therapy had higher 
mortality rates when compared with infants without catechol-
amine therapy, as also reported in other studies.20 21 This might 
be due to confounding by indication, since drug treatment in 
our study was not randomised, for example, epinephrine is a 
standard drug for cardiopulmonary resuscitation. Within the 
subgroup of infants receiving catecholamine therapy, infants 
with high genetic blood pressure estimates had a 50% lower 
mortality rate. This supports the view that genetic predis-
position to high blood pressure has only moderate effects on 
resting blood pressure, but might be lifesaving by enhancing the 
response to catecholamine therapy in life- threatening situations. 
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high (>75th percentile), 
n=1395
Mortality 63/1395 (4.5%) 106/2790 (3.8%) 40/1395 (2.9%) 1.60 (1.07–2.40) 0.027
Mortality within the first 28 days 44/1395 (3.2%) 66/2790 (2.4%) 21/1395 (1.5%) 2.13 (1.26–3.60) 0.005
Intraventricular haemorrhage (IVH) 280/1393 (20.1%) 1497/2788 (17.8%) 237/1395 (17.0%) 1.23 (1.02–1.49) 0.036
IVH grade III or IV 97/1392 (7.0%) 174/2787 (6.2%) 73/1393 (5.2%) 1.35 (0.99–1.85) 0.058
Periventricular leukomalacia 49/1392 (3.5%) 88/2786 (3.2%) 50/1392 (3.6%) 0.98 (0.66–1.46) 1.000
Bronchopulmonary dysplasia 270/1394 (19.4%) 511/2784 (18.4%) 261/1394 (18.7%) 1.04 (0.86–1.26) 0.700
Sepsis 177/1393 (12.7%) 338/2785 (12.1%) 171/1393 (12.3%) 1.04 (0.83–1.30) 0.775
Surgery for necrotising enterocolitis 30/1395 (2.2%) 71/2790 (2.5%) 35/1395 (2.5%) 0.85 (0.52–1.40) 0.616
Surgery for persistent ductus arteriosus 73/1395 (5.2%) 117/2790 (4.2%) 47/1395 (3.4%) 1.58 (1.09–2.30) 0.019
Surgery for retinopathy of prematurity 
or vascular endothelial growth factor 
antibodies
51/1395 (3.7%) 99/2790 (3.5%) 43/1395 (3.1%) 0.70 (0.43–1.14) 0.463
*Two- sided p value comparing groups with low vs high gsBP. Fisher’s exact test was used to compare variables.
Our data furthermore indicate that timing and dosage of current 
blood pressure treatment is not sufficient for all patients, and 
that a more personalised approach is needed.
Although inherited factors account for a substantial amount 
of blood pressure variance (and hypertension), it is still unclear 
why genetic predisposition for high blood pressure is so frequent 
in adults.22 Polymorphisms which were used for calculation and 
group assignment in our study were identified in a very large 
genome- wide association study involving >200 000 adults of 
European descent. In adults, genotypes which are associated with 
high blood pressure are robust risk factors for negative outcomes 
including stroke and coronary artery disease.15 Current concepts 
assume that a genetic background of high blood pressure is a 
neutral factor at birth and during early childhood, but results 
in high incidence of death due to cardiovascular causes later 
in life.23 24 Our data suggest that genetic traits for high blood 
pressure in adults are also associated with higher blood pressure 
in very premature infants. It is reasonable to assume that these 
traits are also associated with higher blood pressure in neonates, 
raising the question if they have been positively selected during 
human evolution because they are associated with lower death 
rates in infancy.25
In addition to lower mortality rates, infants with high gsBP 
had also lower rates of IVH, confirming previous reports that 
treatment of isolated hypotension might be helpful to reduce the 
burden of IVH.12
It must be emphasised that our data do not provide guidance 
with regard to intravenous volume therapy and catecholamine 
therapy itself. Although we observed substantial beneficial 
effects of genetic predisposition to high blood pressure, it is 
uncertain how effective blood pressure in preterm infants can be 
stabilised and if current treatment concepts (ie, early dopamine, 
dobutamine) have similar effects as genetic predisposition. These 
important questions can only be solved by adequately powered 
prospective randomised trials.26 27
Meta- analysis of late cord clamping, which increases intravas-
cular volume after birth, demonstrated a reduced mortality rate 
in the treatment groups,17 although a large- scale randomised 
controlled trial did not find a significant difference for death or 
major morbidity.28 These data indicate that a sufficient volume 
therapy is very important for postnatal stabilisation of preterm 
infants. However, in the GNN most centres already practice 
either late cord clamping or cord milking. Despite this fact, 
infants with a predisposition for higher blood pressures had a 
survival advantage.
Our study has several limitations. Due to the minimal effect 
size of each polymorphism, the lack of systolic and diastolic 
blood pressure levels of infants and the much lower size of our 
cohort compared with adult datasets, we were not able to test 
the direct effects of single polymorphisms on blood pressure in 
preterm infants. This should be done with genome- wide associ-
ation studies in preterm infants. Ideally, such studies will be able 
to analyse continuous blood pressure data and more endogenous 
exposures like cortisol levels and exogenous exposures like cate-
cholamine dosing. This will hopefully result in identification of 
genetic variants with higher effect size and more specific scores 
which can be used for therapeutic decisions. Furthermore, our 
study only included infants of European descent and is therefore 
not generalisable to other populations.Although our results were 
unchanged if mothers with preeclampsia were excluded (data 
not shown), we were not able  to test the effect of maternal 
hypertension, since maternal blood pressure data are not 
recorded in the GNN. Another limitation of our study is its focus 
on short- term outcomes. Genetically estimated blood pressure is 
a lifelong predisposition. Long- term outcome will be interesting, 
since the benefits of high estimated blood pressure with regard 
to such an important outcome measure like death suggest that 
long- term neurodevelopmental outcome of these infants might 
be superior as well.
Our data support causal protective effects of genetic deter-
mination to high blood pressure with regard to mortality in 
preterm infants. This effect was independent from catechol-
amine support and occurred within the first 4 weeks of life, 
suggesting that infants with a predisposition to low blood pres-
sure might benefit from additional medications or altered treat-
ment schedules (ie, personalised therapy). Long- term outcome 
data are pending. Future randomised controlled trials treating 
hypotension in preterm infants should consider the genetic 
predisposition of patients who are enrolled.
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